Thus, our data fit perfectly to pre-clinical data investigating the efficiacy of anti-survivin therapies and might therefore fill the gap in identifying novel therapeutic targets particularly for the treatment of highly aggressive GEP-NEC that are urgently needed. Here, BIRC5 is linked to neuroendocrine carcinoma.